AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01654328
Drug: Sodium chloride tablets
RxNorm normalized name: Sodium Chloride Tablets
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
Trial: NCT04126460
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab is a type of PD-1 antibody
Trial: NCT02318407
Drug: AMG 403
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 403 for the treatment of subjects with osteoarthritis
Trial: NCT02191098
Drug: ALT-803
RxNorm normalized name: ALT-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin 15 (IL-15) is a common γ-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells
Trial: NCT00147485
Drug: AG-024322
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01565148
Drug: iCo-007 350 mcg
RxNorm normalized name: iCo-007
DrugBank: iCo-007 (DB05268)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4
Trial: NCT01565148
Drug: iCo-007 700 mcg
RxNorm normalized name: iCo-007
DrugBank: iCo-007 (DB05268)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4
Trial: NCT01565148
Drug: iCo-007 350 mcg and Laser
RxNorm normalized name: iCo-007
DrugBank: iCo-007 (DB05268)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
Trial: NCT01565148
Drug: Ranibizumab and iCo-007 350 mcg
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later
Trial: NCT01847872
Drug: IPV IM Needle
RxNorm normalized name: NEEDLE
DrugBank: Pine needle oil (pinus mugo) (DB11276)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01847872
Drug: IPV ID Needle
RxNorm normalized name: NEEDLE
DrugBank: Pine needle oil (pinus mugo) (DB11276)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04583267
Drug: tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration
RxNorm normalized name: emtricitabine
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will take tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration for preventing HIV infection.
Trial: NCT03908333
Drug: Paclitaxel protein-bound
RxNorm normalized name: Paclitaxel Protein-Bound
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
Trial: NCT03908333
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg/m2 in 500 mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
Trial: NCT03908333
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 in 500 mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
Trial: NCT00838253
Drug: Istaroxime
RxNorm normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
Trial: NCT00838253
Drug: Istaroxime
RxNorm normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
Trial: NCT00838253
Drug: Istaroxime
RxNorm normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
Trial: NCT03932981
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide at a monthly standard dose of 150-200 mg/m2/day at day 1 to day 5 for a duration of treatment of 12 months
Trial: NCT02647268
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin, 10-5M solution
Trial: NCT02647268
Drug: Magnesium Sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulphate, 3.5mM solution
Trial: NCT00529659
Drug: Comparator: MK-0773
DrugBank: MK-0773 (DB16244)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0773 50 mg tablets twice daily, 6 month treatment period
Trial: NCT01823133
Drug: gemigliptin only
RxNorm normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemigliptin 50mg qd on day 1\~7
Trial: NCT03005678
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: active treatment group
Trial: NCT03005678
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparator
Trial: NCT00268671
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004056
Drug: asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004056
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004056
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004056
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004056
Drug: thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04321031
Drug: PF-06865571
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00555412
Drug: A - 10 mg loxapine q 4 h x 3 (30 mg total)
RxNorm normalized name: loxapine 10 MG
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loxapine aerosol inhalation high dose regimen (30 mg total)
Trial: NCT00555412
Drug: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loxapine aerosol inhalation middle dose regimen (20 mg total)
Trial: NCT00555412
Drug: C - 5 mg loxapine q 4 h x 3 (15 mg total)
RxNorm normalized name: nicotine 0.875 MG/HR [Nicoderm C-Q]
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loxapine aerosol inhalation low dose regimen (15 mg total)
Trial: NCT01077635
Drug: Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HIV-1 infected children currently or having ever been exposed to FPV (+/- 20% of 18mg/kg BID + RTV)
Trial: NCT01538719
Drug: Rilonacept
RxNorm normalized name: Rilonacept
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to active study drug will receive Rilonacept 320 mg subcutaneously (SQ) on day 0 and 160 mg SQ each week for 5 additional weeks
Trial: NCT03010631
Drug: Cohort 1: Lubiprostone Capsule, Fasted
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lubiprostone soft gelatin capsule administered under fasted conditions
Trial: NCT03010631
Drug: Cohort 1: Lubiprostone Sprinkle Formulation, Fasted
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lubiprostone sprinkle formulation administered under fasted conditions
Trial: NCT03010631
Drug: Cohort 2: Lubiprostone Sprinkle Formulation, Fed
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lubiprostone sprinkle formulation administered under fed conditions
Trial: NCT03010631
Drug: Cohort 2: Lubiprostone Sprinkle Formulation, Fasted
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lubiprostone sprinkle formulation administered under fasted conditions
Trial: NCT00018603
Drug: guanfacine
RxNorm normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01169103
Drug: recombinant human growth hormone (rhGH)
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial rhGH dose 0.4mg administered by subcutaneous injection daily. Dose will be increased to 0.6 mg after one week and then increased to 0.8mg after two weeks.
Trial: NCT02724358
Drug: Rg3
RxNorm normalized name: RG3039
DrugBank: D-157495 (DB16938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg, BID, maintained though Month 12.
Trial: NCT00879788
Drug: Ramipril 10mg capsules
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02096471
Drug: PD-0325901
RxNorm normalized name: PD-0325901
DrugBank: Mirdametinib (DB07101)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00432354
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03061227
Drug: Intravenous glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Randomized application of glucagon or saline during oral glucose tolerance test
Trial: NCT01337791
Drug: Telbivudine treatment
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment
Trial: NCT04321031
Drug: PF-05221304
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT02634541
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Biologic drug
Trial: NCT00295724
Drug: Bicifadine
RxNorm normalized name: Bicifadine
DrugBank: Bicifadine (DB04889)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01582815
Drug: JNJ-40411813
RxNorm normalized name: JNJ-40411813
DrugBank: JNJ-40411813 (DB12059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type= range, unit= mg, number= 25 to 150, form= capsules, route= oral administration. JNJ-40411813 will be administered twice daily during 8 weeks, following fixed and flexible schedules in which the dose can range from 25 mg to 150 mg.
Trial: NCT01339104
Drug: Regorafenib (Stivarga, BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All subjects will receive regorafenib administered from Day 1 -21 at a dose of 160 mg od (4 x 40 mg tablets) followed by a 7 days break in repeating cycles of 28 days. The drug is to be taken in the morning with approximately 240 mL of water after having a low fat breakfast. Holter ECGs with triplicate measurements will automatically be obtained at specified timepoints over 24 hours on days -1 and Cycle 1, Day 21. PK samples will be drawn on Cycle 1, Day 21. PK timepoints are time-matched with Holter ECG timepoints. 24 hour urine will be collected beginning on Cycle 1, Day 21. MUGA scans will be done at screening, Cycle 2 Day 21 (after 42 doses of BAY73-4506), then every 3 cycles starting in Cycle 5, and at end of treatment.
Trial: NCT01040494
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all eligible patients will be randomized to receive aliskiren 150 mg on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
Trial: NCT02176005
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin is used alone or associated to DAV132
Trial: NCT04622111
Drug: Metformin hydrochloride 750 mg
RxNorm normalized name: metformin hydrochloride 750 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IMP is a tablet with Metformin hydrochloride as an Active Pharmaceutical Ingredient (API).
Trial: NCT03549975
Drug: Botulinum Toxin Type A 100 unit/Vial (Product)
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum toxin type A injection followed by functional electrical stimulation
Trial: NCT02531152
Drug: Latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01939171
Drug: Thymoglobulin
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02728310
Drug: Levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An infusion rate of 10 ml/h of 1500 mg of 0.5 % of levobupivacaine for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
Trial: NCT02728310
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An infusion rate of 10 ml/h of 300 ml of saline solution for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
Trial: NCT01755390
Drug: Cabazitaxel (XRP6258)
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: infusion solution Route of administration: Intravenous
Trial: NCT02246049
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02246049
Drug: Irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02246049
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03662958
Drug: Enantone
RxNorm normalized name: Prasterone enantate
DrugBank: Prasterone enantate (DB16625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: market reference leuprolide acetate 3.75 mg depot
Trial: NCT02349633
Drug: PF-06747775
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02349633
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02349633
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01572181
Drug: Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * IV fludarabine (30 mg/m²/day for 5 days)~* IV Busulfan (Busilvex 3.2 mg/kg/day for 4 days) (the Busulfan dose is to be adapted to the weight of the child according to the drug label)~* Anti-thymocyte globulines (Thymogolubuline, 2.5 mg/kg/day for 2 days).
Trial: NCT00010400
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01512199
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
Trial: NCT01512199
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel: 175 mg/m\^2 administered intravenously once every three weeks
Trial: NCT00793858
Drug: placebo, isotonic ciclesonide, hypotonic ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mcg/nostril
Trial: NCT02343042
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablets
Trial: NCT02343042
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tablets
Trial: NCT02343042
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral capsule
Trial: NCT02343042
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tablets
Trial: NCT02343042
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous Injection (single use vial)
Trial: NCT02343042
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous Infusion
Trial: NCT02343042
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT02343042
Drug: Ixazomib
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral capsule
Trial: NCT02343042
Drug: Elotuzumab
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT02343042
Drug: Belantamab Mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous infusion
Trial: NCT02343042
Drug: Mezigdomide
RxNorm normalized name: Mezigdomide
DrugBank: Mezigdomide (DB17584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsules
Trial: NCT00284336
Drug: Caelyx
RxNorm normalized name: Caelyx
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00284336
Drug: endoxan
RxNorm normalized name: Endoxana
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00122317
Drug: eculizumab
RxNorm normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00651781
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 times per week of Velcade administration.
Trial: NCT01003158
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV once weekly for 3 weeks followed by a week off
Trial: NCT00325715
Drug: esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00262561
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The effect of Aspirin on platelet function was assessed.
Trial: NCT03476928
Drug: Vilaprisan (BAY1002670)
RxNorm normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg, once daily, oral
Trial: NCT01733875
Drug: CC-220 1 mg
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of CC-220 1 mg will be administered orally once a day.
Trial: NCT01733875
Drug: CC-220 2 mg
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of CC-220 2 mg will be administered orally once a day.
Trial: NCT01733875
Drug: CC-220
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-220 4 mg will be administered orally once a day
Trial: NCT01733875
Drug: CC-220
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-220 6 mg will be administered orally once a day
Trial: NCT01733875
Drug: CC-220
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-220 1 mg will be administered orally once a day in each of 2 study periods - once with food and once without food
Trial: NCT03001557
Drug: Lemborexant 2.5 mg
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lemborexant 2.5 mg tablets
Trial: NCT03001557
Drug: Lemborexant 5 mg
RxNorm normalized name: lemborexant 5 MG
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lemborexant 5 mg tablets
Trial: NCT01875666
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg/kg IV, single dose
Trial: NCT01875666
Drug: pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 840 mg IV single dose